NIBSC - Update 15 1st March

Enter a search term

Home Page > Spotlight > Influenza Resource Centre > Reagents > Update Archive

Update 15 1st March

Current availability from NIBSC of candidate influenza vaccine viruses, SRD reagents and neuraminidase reagents for use in the 2010/2011 northern hemisphere season, 2010 southern hemisphere season and the 2009/2010 northern hemisphere season. (See below for pricing information)

Update 15, 1 March 2010

Northern Hemisphere 2010/2011 and Southern Hemisphere 2010¹

Candidate influenza vaccine viruses	NIBSC code
H1N1
A/California/7/2009 wild type virus ²	09/104
NYMC X-179A reassortant derived from A/California/7/2009	09/216
NYMC X-181 reassortant derived from A/California/7/2009	09/176
NYMC X-181A reassortant derived from A/California/7/2009	09/178
IVR-153 reassortant derived from A/California/7/2009	09/236
NIBRG-121 reassortant derived from A/California/7/2009	09/122
NIBRG-121xp reassortant derived from A/California/7/2009	09/268
NIBRG-122 reassortant derived from A/England/195/2009	09/130
H3N2
A/Perth/16/2009 wild type virus	09/208
NIB-64 reassortant derived from A/Perth/16/2009	09/206
NYMC X-183 reassortant derived from A/Wisconsin/15/2009	09/248
NYMC X-185 reassortant derived from A/Guangdong-Luohu/1256/2009	09/274
NYMC X-187 reassortant derived from A/Victoria/210/2009	09/290
NIB-65 reassortant derived from A/Victoria/210/2009	09/298
IVR-155 reassortant derived from A/Victoria/210/2009	09/304
B
B/Brisbane/60/2008	09/168
B/Brisbane/33/2008	08/280
NYMC BX-31 reassortant derived from B/Brisbane/60/2008	08/360
NIB-58 reassortant derived from B/Brisbane/60/2008	08/364

¹ WHO recommendations for influenza virus vaccines for use in the 2010/2011 northern hemisphere influenza season

² For further information on the candidate (H1N1)v vaccine viruses

Reagents for influenza vaccine standardisation	NIBSC code
H1N1
A/California/7/2009 (NYMC X-179A) egg derived antigen	09/146
A/California/7/2009 (NYMC X-179A) cell derived antigen	09/174
A/California/7/2009 (NIBRG-121xp) egg derived antigen	09/196
A/California/7/2009 (NYMC X-181)	09/294
A/California/7/2009 antiserum	09/152
H3N2
A/Perth/16/2009 like antigen	tbc
A/Perth/16/2009 like antiserum	09/270
B
B/Brisbane/60/2008 like antigen	08/352
B/Brisbane/60/2008 like antiserum	08/354

Neuraminidase reagents	NIBSC code
N1
antiserum prepared from A/New Caledonia/20/99	04/230
N2
antiserum prepared from A/Wyoming/3/2003	04/258
B
NA antiserum prepared from B/Jiangsu/10/2003	04/228
NA antiserum prepared from B/Malaysia/2506/2004	05/252
NA antiserum prepared for B/Florida/4/2006 under development	To be confirmed

Northern Hemisphere 2009/2010 ³

Candidate influenza vaccine viruses	NIBSC code
H1N1
A/Brisbane/59/2007	09/276
IVR-148 reassortant derived from A/Brisbane/59/2007	08/300
H3N2
A/Brisbane/10/2007 wild type virus	07/250
A/Uruguay/716/2007 wild type virus-	07/354
NIB-50 reassortant derived from A/Uruguay/716/2007	07/358
IVR-149 reassortant derived from A/Uruguay/716/2007	07/362
NYMC X-175C reassortant derived from A/Uruguay/716/2007	08/304
B
B/Brisbane/60/2008	09/168
B/Brisbane/33/2008	08/280
NYMC BX-31 reassortant derived from B/Brisbane/60/2008	08/360
NIB-58 reassortant derived from B/Brisbane/60/2008	08/364

Reagents for influenza vaccine standardisation	NIBSC code
H1N1
A/Brisbane/59/2007 IVR-148 antigen	08/100
A/Brisbane/59/2007 IVR-148 antiserum	08/112
H3N2
A/Brisbane/10/2007-like antigen (NYMC X-175C derived from A/Uruguay/716/2007)	08/278
A/Brisbane/10/2007-like antiserum (NYMC X-175C derived from A/Uruguay/716/2007)	08/246
B
B/Brisbane/60/2008 like antigen	08/352
B/Brisbane/60/2008 like antiserum	08/354

Neuraminidase reagents	NIBSC code
N1
antiserum prepared from A/New Caledonia/20/99	04/230
N2
antiserum prepared from A/Wyoming/3/2003	04/258
B
NA antiserum prepared from B/Jiangsu/10/2003	04/228
NA antiserum prepared from B/Malaysia/2506/2004	05/252
NA antiserum prepared for B/Florida/4/2006 available from w/c 22 March 2010	To be confirmed

Pricing information

Viruses are free of charge (normally a maximum of two vials per recipient), but customers are expected to pay shipping and packing costs. Reagents for Single Radial Diffusion assay are subject to the usual NIBSC handling charge of £63 per vial, plus shipping and packing costs. Approved National Control Laboratories for human health are exempt from the £63 handling fee.